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Abstract
Background: The relevance of angiogenesis inhibition in the treatment of glioblastoma multiforme
(GBM) should be considered in the unique context of malignant brain tumours. Although patients
benefit greatly from reduced cerebral oedema and intracranial pressure, this important clinical
improvement on its own may not be considered as an anti-tumour effect.
Discussion: GBM can be roughly separated into an angiogenic component, and an invasive or
migratory component. Although this latter component seems inert to anti-angiogenic therapy, it is
of major importance for disease progression and survival. We reviewed all relevant literature.
Published data support that clinical symptoms are tempered by anti-angiogenic treatment, but that
tumour invasion continues. Unfortunately, current imaging modalities are affected by anti-
angiogenic treatment too, making it even harder to define tumour margins. To illustrate this we
present MRI, biopsy and autopsy specimens from bevacizumab-treated patients.
Moreover, while treatment of other tumour types may be improved by combining chemotherapy
with anti-angiogenic drugs, inhibiting angiogenesis in GBM may antagonise the efficacy of
chemotherapeutic drugs by normalising the blood-brain barrier function.
Summary: Although angiogenesis inhibition is of considerable value for symptom reduction in
GBM patients, lack of proof of a true anti-tumour effect raises concerns about the place of this type
of therapy in the treatment of GBM.
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Background
The brain is the highest organised and most complex
organ of the body. Some unique features of the brain that
have an impact on the biology of brain tumours include
extensive three-dimensional structuring with gray and
white matter [1], and high density of blood capillaries
making it a well-perfused organ; however, a blood-brain
barrier (BBB) very selectively regulates the penetration of
substances into the brain [2]. With respect to this specific
micro-environment, brain cancer, in particular high-grade
astrocytoma (malignant glioma, glioblastoma multi-
forme, GBM) differs from many other cancer types.
Whereas this disease usually manifests itself as a focal
lesion with central necrosis surrounded by an angiogenic
tumour rim (one of the characteristics of GBM), this
tumour also invades the surrounding extracellular matrix,
using both white matter tracts and blood vessels as sub-
strate [3,4]. Consequently, the presence of migrating gli-
oma cells in brain parenchyma relatively far away from
the tumour core is common, complicating curative sur-
gery and radiotherapy. The exact molecular and cellular
mechanisms behind cell migration in glioma remain to be
elucidated [5].
Despite attempts to improve treatment results over the
last 30 years, GBM remains a highly fatal and devastating
disease; a cure is extremely rare, even with aggressive treat-
ment [6,7]. The current standard of care is surgical resec-
tion to a maximal feasible extent, followed by
radiotherapy and systemic temozolomide (TMZ) chemo-
therapy. The latter has a modest effect on outcome, with a
median overall survival of 14.6 months versus 12.1
months for radiotherapy alone [8]. Consequently, with so
few treatment options available, the latest regimens
designed for treatment of other cancers are currently also
tested for GBM. These new agents include angiogenesis
inhibitors, in particular bevacizumab (Avastin®). Com-
bined with chemotherapy, this monoclonal antibody
against VEGF-A is FDA approved for the treatment of
advanced non small-cell lung cancer, advanced breast can-
cer and advanced colorectal cancer, improving overall sur-
vival in these patients compared with chemotherapy
alone [9-13]. Indeed, results of phase II non-randomised
trials with angiogenesis inhibitors for recurrent GBM
seem promising, with substantial improvement of appar-
ent median progression-free survival (PFS) and 6-months
PFS6 compared with historical controls [14-17]. Due to a
lack of large phase III studies, reliable data on overall sur-
vival prolongation are not available. Yet, based on data
from phase II studies, bevacizumab received accelerated
FDA approval for treatment of recurrent high-grade astro-
cytomas in May 2009.
Despite these apparent improvements it should also be
realised that the characteristic tumour micro-environment
in brain may have a negative impact on the efficacy of
such therapies, and may even be responsible for overesti-
mation of efficacy. We outline below how the unique fea-
tures of GBM may provide this type of tumour with an
'escape mechanism' from anti-angiogenic treatment, and
present clinical and histological data that confirm results
from preclinical work on orthotopic glioma xenografts.
While angiogenesis inhibitors in combination with chem-
otherapies may effectively inhibit tumour cell prolifera-
tion in other tumour types, the brain micro-environment
allows furtive invasion and proliferation in case of GBM.
Discussion
Clinical experiences
One of the aggravating symptoms of high-grade astrocyto-
mas is increased intracranial pressure, a direct result of
oedema caused by leaky tumour vasculature. Corticoster-
oids are used to alleviate these symptoms [18]. Angiogen-
esis inhibitors are also effective in reducing these
symptoms, or in reducing the need for corticosteroid
treatment in recurrent GBM patients [19-26]. This rapid
effect of anti-VEGF therapy is suggested to be due to a nor-
malization of vascular permeability resulting in a reduc-
tion of peritumoural oedema and intracranial pressure,
and is even more active than corticosteroid therapy alone
(Figure 1A-C) [21,24].
However, the question remains whether angiogenesis
inhibitors represent a true anti-GBM regimen. Non-ran-
domised phase II trials in recurrent GBM patients demon-
strated high response rates ranging from 20% with single
agent TMZ [27], to 30% with single agent AZD2171
(Cediranib, a small molecule VEGFR inhibitor) [24], 20%
with single agent bevacizumab, and even to 57% when
bevacizumab was combined with irinotecan [14-17,28].
These studies also demonstrated longer median PFS (14-
24 weeks), and 6-months PFS (17%-46%), compared
with historical controls treated with cytotoxic chemother-
apy (6-months PFS mostly <30%). Although some have
reported relatively long median survival (34-42 weeks)
[14,16,28], Norden et al. [29] demonstrated a longer
median PFS (8 vs. 22 weeks), but not median survival (39
vs. 37 weeks), of recurrent GBM patients treated with anti-
angiogenic therapy. The suggested efficacy of anti-ang-
iogenic drugs in patients with recurrent GBM is based on
non-randomised trials with PFS as the main study end-
point.
Determination of the precise time at which GBM progres-
sion occurs is challenging. The often robust and sustained
changes on MRI by anti-angiogenic drugs may render sub-
sequent MRI scans difficult to interpret [30]. Therefore,
the response rate and PFS may not be the optimal end-
points in phase II studies of anti-angiogenic therapy in
patients with recurrent GBM. Because of the potentialBMC Cancer 2009, 9:444 http://www.biomedcentral.com/1471-2407/9/444
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selection bias in non-randomised studies, and concerns
about PFS as study endpoint, we should interpret data
from such studies with caution [31]. Randomised trials
with survival as primary endpoint are necessary to deter-
mine the role of angiogenesis inhibitors in the treatment
of patients with recurrent GBM.
A problem with the current enthusiasm for angiogenesis
inhibition in GBM is that tumour response evaluations
are based on cross sectional contrast enhancing tumour
areas [32]. Because anti-angiogenic therapy directly inter-
feres with vessel permeability and gadolinium-DTPA (Gd-
DTPA) uptake in the tumours, response evaluations based
on contrast enhancing areas are suboptimal for monitor-
ing the effects of anti-angiogenic therapy [30]. In addi-
tion, the current methods of imaging are not adequate to
identify tumour boundaries, the areas where tumour
growth and infiltration takes place. Indeed, also in mouse
models of orthotopic glioma, tumour visibility on Gd-
DTPA-enhanced MRI scans show an impressive decrease
after anti-angiogenic treatment. However, in these models
treatment does not affect tumour growth, but merely
shifts tumour progression from an expansive to an inva-
sive, angiogenesis-independent phenotype [33,34].
MRI scans of recurrent GBM treated with bevacizumab Figure 1
MRI scans of recurrent GBM treated with bevacizumab. MRI scans of a typical patient with recurrent GBM, treated 
with bevacizumab 10 mg/kg every 3 weeks plus daily temozolomide 50 mg/m2. Top row T1; middle row T2; bottom row ADC 
(apparent diffusion coefficient. ADC c is lacking). Column (A) scans pre-treatment, showing cystic and tumour component, 
large midline shift, and large vasogenic oedema. Column (B) 3 days after start, showing reduced contrast enhancement, and 
slightly reduced midline shift. Column (C) 21 days after start, showing reduced contrast enhancement but a larger size (no pro-
gression based on Macdonald criteria), reduced midline shift, and reduced oedema. Column (D) 88 days after start, showing 
decreased size of tumour and cystic component, stable reduction of contrast enhancement, normalised midline shift, and slight 
increase of oedema. Column (E) 188 days under treatment, showing increased tumour size and cystic component, increased 
midline shift, and increased oedema (also in the other hemisphere).BMC Cancer 2009, 9:444 http://www.biomedcentral.com/1471-2407/9/444
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Therefore, also in patients with GBM, the impressive
decreases of contrast enhancement in these tumours on
anti-angiogenic treatment (Figure 1A-E) are not necessar-
ily synonymous with anti-tumour effects.
In the 1990s, MRI criteria for evaluation of brain tumour
size and treatment responses were adjusted after introduc-
tion of corticosteroids in GBM treatment [35]. Again, new
criteria need to be developed now that angiogenesis
inhibitors are being explored for the treatment of GBM
and, importantly, for other tumours that metastasise to
the brain [36-41]. Promising imaging modalities to evalu-
ate anti-angiogenic treated patients include T2-weighted
imaging [42], dynamic contrast enhancement imaging
[43], apparent diffusion coefficient imaging [44], diffu-
sion tension imaging [45], diffusion-weighted imaging
[46], USPIO-enhanced blood volume imaging [34], (mul-
tivoxel) MR spectroscopy [42], positron emitting tomog-
raphy [47,48], and single-photon emission computed
tomography nuclear imaging [49]. However, the clinical
value of these modalities for the follow-up of GBM
patients treated with angiogenesis inhibitors in trials has
yet to be confirmed [50].
Vascularisation and vessel normalisation
The central hypothesis of angiogenesis inhibition as anti-
tumour strategy states that tumour growth and expansion
are dependent on the ability of the tumour to generate its
Recurrent GBM: resection and autopsy material, post bevacizumab Figure 2
Recurrent GBM: resection and autopsy material, post bevacizumab. (A, B) Recurrent GBM resection material, 
obtained 6 weeks after last infusion of bevacizumab. Tumour cells co-opt pre-existent vessels with relatively intact BBB 
(arrows). (A) H&E staining 20×. (B) Glut-1, BBB marker, 20×. (C, D) Recurrent GBM: autopsy was performed 10 weeks after 
the last infusion of bevacizumab. Near tumour sample shows tumour cells invading along white matter tracks. (C) H&E 20×. 
(D) Glut-1 BBB marker, 10×.BMC Cancer 2009, 9:444 http://www.biomedcentral.com/1471-2407/9/444
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own supportive vascularisation [51-53]. The actual
dependence on angiogenesis is, however, highly depend-
ent on the tumour micro-environment. Indeed, it is an
absolute requirement for rapidly proliferating tumours
growing in avascular spaces, which encompass most of
the subcutaneous murine tumour models (including gli-
oma). Such tumours are indeed very responsive to anti-
angiogenic therapy. In clinical tumours (and, in particu-
lar, brain cancer), the situation is far more complex. While
GBM is considered to be a highly vascular tumour with an
extensive angiogenic component driven by VEGF-A (pro-
duced by peri-necrotic hypoxic tumour cells), the relative
contribution of angiogenic growth aspects is probably low
compared to the complete tumour volume. In the ang-
iogenic parts, the quality of the newly formed vessels may
be poor [54,55]. Theoretical and preclinical models sup-
port the concept that anti-angiogenic treatment leads to
vascular normalisation in these areas; immature intratu-
moural vessels are pruned, vessel hyperpermeability and
concomitant tumour interstitial pressure are reduced, and
pericyte coverage is restored, resulting in improved
tumour vessel perfusion and creating opportunities for
combination treatments [56,57]. Vessel normalisation is
believed to explain the synergy between bevacizumab and
chemotherapy in advanced colorectal cancer patients
[9,57]. In confirmation of this concept, it was recently
reported that anti-VEGF treatment of subcutaneous
melanoma grafts results in vessel normalisation and con-
comitant better delivery of MRI contrast agents and oxy-
gen to the tumour [58]. In striking contrast, similar
treatment of brain tumours (both primary and metastatic)
results in reduced contrast-enhanced MRI visibility both
in animal models [34,59] and in GBM patients (Figure 1).
Thus, functional implications of vessel normalisation
may depend on specific features of the tumour micro-
environment, enabling an adaptation to circumvent the
specific angiogenic blockade [60].
Invasion and migration
Next to the angiogenic rim, in GBM large areas can be
identified where viable and proliferating tumour cells
invade the surrounding highly vascularised normal tissue.
In the cerebrum, blood vessels and white matter tracts are
typically located next to each other and form corridors for
invading GBM cells [4]. Close to the tumour bulk, glioma
cells can be found alongside these vessels and white mat-
ter tracts (Figure 2A-D) [61]. Utilisation of these blood
vessels for metabolic support (known as vessel co-
option), offers proliferating tumour cells an efficient
escape mechanism for anti-angiogenic therapy. Indeed,
co-opted vessels are refractory to anti-angiogenic treat-
ment [33,56,62-65]. Consequently, even during anti-ang-
iogenic therapy, GBM cells continue to migrate through
the adjacent cerebrum for considerable distances as is
illustrated by the presence of high densities of tumour
cells, disperse throughout the brain of a patient who died
10 weeks after the last dose of bevacizumab (Figure 3).
Published clinical data appear in line with recently pub-
lished preclinical data, showing that VEGF inhibition may
promote tumour cell invasiveness, also in other tissues
than brain [66-69]. Clinical studies have also shown that
bevacizumab may alter the recurrence pattern of malig-
nant gliomas by suppressing contrast-enhancing tumours
more effectively than non-enhancing, infiltrative tumours
[22,70].
Blood brain barrier and chemotherapy
Chemotherapeutic drugs are generally not very effective
against GBM, partly due to intrinsic resistance [71] but
also because of an intact BBB in peripheral parts of the
tumour (note the positive staining for BBB-specific
endothelial protein glut-1 in Figure 2B,D) that efficiently
restricts the distribution of drugs to tumour cells [2]. Even
TMZ, which is able to cross the BBB to some extent, prob-
ably acts more effectively against tumour cells in more
accessible angiogenic parts of the tumour. The synergy of
combined anti-angiogenic and chemotherapeutic agents
in other malignancies has been partially attributed to nor-
malisation of the tumour vascular bed, as discussed above
[53]. Whereas this strategy may work well in tumours out-
side the brain, in case of GBM normalisation of the
tumour vascular bed and reduction of interstitial pressure
comes at the expense of restored functionality of the BBB
as evidenced by the reduced permeability for Gd-DTPA.
The accompanying reduced accessibility of other drugs
carries the risk of antagonising the efficacy of such agents;
Recurrent GBM: autopsy material, post bevacizumab Figure 3
Recurrent GBM: autopsy material, post bevacizu-
mab. GBM cells invade almost the whole brain of this recur-
rent GBM patient (2C, D). H&E stained autopsy specimen of 
neocortex of the hemisphere opposite to tumour location, 
10 weeks after the last infusion of bevacizumab.BMC Cancer 2009, 9:444 http://www.biomedcentral.com/1471-2407/9/444
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Schematic drawing: pre-treatment and during treatment Figure 4
Schematic drawing: pre-treatment and during treatment. Schematic drawing of high-grade glioma, pre-treatment (A), 
and with anti-VEGF treatment (B). (A) Contrast leakage (white) occurs around leaky tumour vessels enhancing the tumour 
area on MRI. Capillaries in surrounding tissue are not leaky. (B) Contrast-enhanced area is strongly reduced under anti-VEGF 
treatment. Tumour cells migrate furtively into the surrounding tissue and co-opt existing vasculature.BMC Cancer 2009, 9:444 http://www.biomedcentral.com/1471-2407/9/444
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we have shown this in mice bearing orthotopic intracra-
nial tumours treated with TMZ either with or without con-
comitant anti-angiogenic treatment with vandetanib
(ZD6474) [59]. More recently, it was reported that bevaci-
zumab increases efficacy of TMZ [72] or carboplatin [73].
At this moment the cause of this apparent discrepancy
remains unclear but effects of timing and dosing of anti-
angiogenic therapy and chemotherapy may play a role
here. For example, we previously demonstrated that high
doses of vandetanib effectively inhibited angiogenesis
and restored vessel permeability, whereas low doses did
inhibit angiogenesis but left tumour vasculature hyper-
permeable [33]. These features should be carefully inves-
tigated for clinical GBM too, to improve control of the
different therapeutic modalities on tumour behaviour.
Meanwhile, the discussion continues as to whether com-
bining anti-angiogenic treatments with other chemother-
apies is beneficial or detrimental (or somewhere in-
between).
Conclusions
The relevance of angiogenesis inhibition in the treatment
of GBM has been placed in the unique context of malig-
nant brain tumours. Patients may benefit from anti-ang-
iogenic therapy by its reduction of peritumoural oedema
and intracranial pressure. Several studies also suggest an
anti-tumour effect because of improved response rates
and prolonged PFS; however, these data are derived from
non-randomised trials with PFS as primary endpoint.
Available data on survival prolongation are less robust
(phase II) and sometimes even conflicting. High costs and
side-effects of angiogenesis inhibitors (e.g. venous and
arterial thrombo-embolism and haemorrhage as demon-
strated in phase II studies) need to be balanced against
advantages related to survival. Therefore, we can only
implement angiogenesis inhibitors as standard treatment
for patients with GBM when data are available from ran-
domised clinical trials with survival as primary endpoint.
Our concerns are not restricted to the limited amount of
data on outcome and toxicity, but also arise from preclin-
ical data on the biology of GBM and angiogenesis inhibi-
tion.
GBM can be roughly separated into an angiogenic compo-
nent, and an invasive or migratory component. Although
this latter component seems inert to anti-angiogenic ther-
apy, it is of major importance for disease progression and
survival (Figure 4). Whereas symptoms are tempered by
anti-angiogenic treatment, furtive invasion of the disease
continues, unrecognised by standard imaging modalities.
Moreover, while treatment of other tumour types is
improved by combining chemotherapy with anti-ang-
iogenic drugs, inhibiting angiogenesis in GBM may antag-
onise the efficacy of chemotherapeutic drugs by
normalising the BBB function. Although angiogenesis
inhibition is of value for symptom reduction in GBM
patients, the possible lack of a true anti-tumour effect
raises concerns about the place of this type of therapy in
the treatment of patients with GBM.
Summary
1. GBM can be roughly separated into an angiogenic com-
ponent, and an invasive or migratory component.
2. Although this invasive or migratory component seems
inert to anti-angiogenic therapy, it is of major importance
for disease progression and survival.
3. Whereas symptoms are tempered by anti-angiogenic
treatment, furtive invasion of the disease continues,
unrecognised by standard imaging modalities.
4. Moreover, while treatment of other tumour types is
improved by combining chemotherapy with anti-ang-
iogenic drugs, inhibiting angiogenesis in GBM may antag-
onise the efficacy of chemotherapeutic drugs by
normalising the BBB function.
5. Although angiogenesis inhibition is of value for symp-
tom reduction in GBM patients, the possible lack of a true
anti-tumour effect raises concerns about the place of this
type of therapy in the treatment of GBM.
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